Cardiotoxicity of contemporary breast cancer treatments Review


Authors: Lee Chuy, K.; Yu, A. F.
Review Title: Cardiotoxicity of contemporary breast cancer treatments
Abstract: Treatment-related cardiotoxicity remains a significant concern for breast cancer patients undergoing cancer treatment and extends into the survivorship period, with adverse cardiovascular (CV) outcomes further compounded by the presence of pre-existing CV disease or traditional CV risk factors. Awareness of the cardiotoxicity profiles of contemporary breast cancer treatments and optimization of CV risk factors are crucial in mitigating cardiotoxicity risk. Assessment of patient- and treatment-specific risk with appropriate CV surveillance is another key component of care. Mismatch between baseline cardiotoxicity risk and intensity of cardiotoxicity surveillance can lead to unnecessary downstream testing, increased healthcare expenditure, and interruption or discontinuation of potentially life-saving treatment. Efforts to identify early imaging and/or circulating biomarkers of cardiotoxicity and develop effective management strategies are needed to optimize the CV and cancer outcomes of breast cancer survivors. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Keywords: breast cancer; cardiotoxicity; cardio-oncology
Journal Title: Current Treatment Options in Oncology
Volume: 20
Issue: 6
ISSN: 1527-2729
Publisher: Springer  
Date Published: 2019-06-01
Start Page: 51
Language: English
DOI: 10.1007/s11864-019-0646-1
PUBMED: 31073788
PROVIDER: scopus
PMCID: PMC7306973
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Anthony Yu
    90 Yu